☆ 4.4 Article

Carboxypeptidase vitellogenic like facilitates resistance to CDK4/6 inhibitors in breast cancer

THORACIC CANCER (2023)

Related references

Note: Only part of the references are listed.

Review Oncology

CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer

Bulent Cetin et al.

Summary: The combination of CDK4/6 inhibitors and endocrine therapy is the preferred treatment for HR-positive, HER2-negative metastatic breast cancer. However, resistance mechanisms and biomarkers predicting the efficacy of CDK4/6 inhibitors are still being studied. This review summarizes the use of CDK4/6 inhibitors in breast cancer and possible approaches to overcome resistance.

FUTURE ONCOLOGY (2022)

Add to Collection

Article Oncology

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

Qing Li et al.

Summary: This study identifies CDK4/6 kinase activation as a common mechanism in oncogenic signaling-induced proliferation and develops a new strategy for inhibiting CDK4/6 kinases to overcome resistance.

CANCER DISCOVERY (2022)

Add to Collection

Article Genetics & Heredity

Relationship Between CNVs and Immune Cells Infiltration in Gastric Tumor Microenvironment

Fazhan Li et al.

Summary: The study found that gene copy number variations are closely related to immune cell infiltration in gastric cancer. By analyzing single-cell sequencing data of gastric cancer and normal cells, five gene signatures highly correlated with copy number variations were identified, and CPVL may be a potential prognostic marker for gastric cancer.

FRONTIERS IN GENETICS (2022)

Add to Collection

Article Oncology

Breast Cancer Statistics, 2022

Angela N. Giaquinto et al.

Summary: This article provides an update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and mammography screening. It shows that breast cancer incidence rates have increased over the past few decades, driven by localized-stage and hormone receptor-positive disease. However, breast cancer mortality rates have been steadily declining since 1989, although at a slower pace in recent years. Despite lower incidence rates, there remains a racial disparity in breast cancer mortality, with higher rates among Black women compared to White women.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer

Hongnan Mo et al.

Summary: The innate resistance mechanism to CDK4/6 inhibitors is S6K1 amplification, which accounts for a certain proportion in breast cancer patients. Patients with S6K1 amplification have poor response to CDK4/6 inhibitors and may benefit from the combination of CDK4/6 and S6K1 antagonists.

MOLECULAR CANCER (2022)

Add to Collection

Review Oncology

Targeting CDK4 and CDK6 in cancer

Shom Goel et al.

Summary: Dysregulation of CDK4 and CDK6 promotes the growth and survival of several cancer types. CDK4/6 inhibitors have become the standard of care for advanced hormone receptor-positive breast cancer. Better understanding of their mechanisms of action and exploring new therapeutic opportunities are crucial.

NATURE REVIEWS CANCER (2022)

Add to Collection

Article Oncology

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

Ryohei Ogata et al.

Summary: Acquired resistance to PAL or ABE in breast cancer cells confers cross-resistance to the other CDK4/6 inhibitor but not to chemotherapeutic agents. Down-regulation of basal RB expression and normalized RB phosphorylation reduced by CDK4/6 inhibitors may be responsible for the attenuated anti-cell growth effects of the inhibitors.

BREAST CANCER (2021)

Add to Collection

Review Pharmacology & Pharmacy

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences

C. Louwrens Braal et al.

Summary: CDK 4/6 inhibitors are a new class of drugs that interrupt proliferation of malignant cells by inhibiting progression through the cell cycle. This article reviews the clinical pharmacokinetic and pharmacodynamic profiles of these inhibitors and discusses important future directions for their clinical applicability.

DRUGS (2021)

Add to Collection

Article Health Care Sciences & Services

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

Hope S. Rugo et al.

Summary: This study compared the overall survival of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with palbociclib+fulvestrant versus ribociclib+fulvestrant and abemaciclib+fulvestrant using matching-adjusted indirect treatment comparisons. The results showed similar overall survival between the treatments, highlighting the importance of adjusting for cross-trial differences in indirect treatment comparisons.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Add to Collection

Article Medicine, Research & Experimental

CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis

Hui Yang et al.

Summary: CPVL is significantly upregulated in glioma cells and tissues, and its high expression is associated with advanced clinical grade and poor prognosis. Silencing CPVL promotes glioma cell apoptosis, inhibits cell proliferation, and suppresses tumorigenicity in vitro and in vivo, potentially through interactions with BTK and modulation of STAT1 phosphorylation.

JCI INSIGHT (2021)

Add to Collection

Review Medicine, General & Internal

Breast cancer

Sibylle Loibl et al.

Summary: Breast cancer diagnosis and treatment have become increasingly complex, incorporating various biomarkers and neoadjuvant therapies, with de-escalation schemes for radiotherapy now becoming standard practice.

LANCET (2021)

Add to Collection

Article Oncology

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

Carlotta Costa et al.

CANCER DISCOVERY (2020)

Add to Collection

Review Pharmacology & Pharmacy

A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib

Qing-Yun Chong et al.

PHARMACOLOGICAL RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER plus breast cancer

Xi Jin et al.

MOLECULAR CANCER (2020)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib

Stefanie L. Groenland et al.

CLINICAL PHARMACOKINETICS (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

Michela Piezzo et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Review Oncology

Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer

Neil Portman et al.

ENDOCRINE-RELATED CANCER (2019)

Add to Collection

Review Oncology

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions

Laura M. Spring et al.

CURRENT ONCOLOGY REPORTS (2019)

Add to Collection

Article Oncology

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients

Marzia Del Re et al.

BREAST CANCER RESEARCH AND TREATMENT (2019)

Add to Collection

Review Oncology

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Kamal Pandey et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors

Shom Goel et al.

CANCER CELL (2016)

Add to Collection

Review Oncology

Treating cancer with selective CDK4/6 inhibitors

Ben O'Leary et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer

Janice Lu

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer

Nicholas C. Turner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Endocrinology & Metabolism

CPVL/CHN2 Genetic Variant Is Associated With Diabetic Retinopathy in Chinese Type 2 Diabetic Patients

Cheng Hu et al.

DIABETES (2011)

Add to Collection

Article Biotechnology & Applied Microbiology

Cloning and characterization of CPVL, a novel serine carboxypeptidase, from human macrophages

JA Mahoney et al.

GENOMICS (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.